PMID- 36699079 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 13 DP - 2022 TI - Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system. PG - 1045561 LID - 10.3389/fphar.2022.1045561 [doi] LID - 1045561 AB - Background: The role of antihypertensive drugs in inducing hyperuricaemia and gout has been a long-term concern in clinical practice. However, clinical studies regarding this issue are limited in number and have yielded inconsistent results. We comprehensively evaluated the association between various antihypertensive drugs and the occurrences of hyperuricaemia, gout and related adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS), aiming to guide the selection of antihypertensive drugs with a goal of minimizing the risk of hyperuricaemia, gout and related AEs. Methods: We used OpenVigil 2.1 to query the FAERS database. Hyperuricaemia, gout and related AEs were defined by 5 Preferred Terms: hyperuricaemia, gout, gouty arthritis, gouty tophus and urate nephropathy. Disproportionality analysis was performed, and a positive signal indicated an association between AEs and antihypertensive drugs. Results: The numbers of antihypertensive drugs with positive signals for hyperuricaemia, gout, gouty arthritis, gouty tophus and urate nephropathy were 46, 66, 27, 8 and 6, respectively. These drugs included diuretics, antihypertensive drugs with central action, alpha blockers, beta blockers, alpha and beta blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, renin inhibitors, vasodilators, and compound preparations. Furthermore, 42 antihypertensive drugs had positive signal for more than one AEs. Conclusion: Our study suggests that some potassium-sparing diuretics, calcium channel blockers and losartan may be associated with increased risk of hyperuricaemia, gout or related AEs, which is inconsistent with most previous studies. Moreover, Our study also suggests that some antihypertensive drugs with central action, alpha and beta blockers, renin inhibitors and vasodilators may be associated with increased risk of hyperuricaemia, gout or related AEs, which has not been reported in previous studies. These findings complement real-world evidence on the potential risks of hyperuricaemia, gout and related AEs associated with antihypertensive drugs. CI - Copyright (c) 2023 Jiao, Song, Jiao, Li, Zeng, Zou, Zhang, Wang and Zhang. FAU - Jiao, Xue-Feng AU - Jiao XF AD - Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China. AD - NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China. FAU - Song, Kunpeng AU - Song K AD - Department of Cardiovascular Medicine Ward II, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China. FAU - Jiao, Xueyan AU - Jiao X AD - Henan University of Traditional Chinese Medicine, Zhengzhou, China. FAU - Li, Hailong AU - Li H AD - Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China. AD - NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China. FAU - Zeng, Linan AU - Zeng L AD - Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China. AD - NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China. FAU - Zou, Kun AU - Zou K AD - Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China. AD - NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China. FAU - Zhang, Wei AU - Zhang W AD - West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China. AD - Medical Big Data Center, Sichuan University, Chengdu, China. FAU - Wang, Huiqing AU - Wang H AD - Medical Simulation Centre, West China Second University Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Lingli AU - Zhang L AD - Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China. AD - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China. AD - NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China. AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China. AD - Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20230109 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC9868414 OTO - NOTNLM OT - adverse events OT - antihypertensive drugs OT - gout OT - hyperuricaemia OT - the FDA adverse event reporting system COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/27 06:00 MHDA- 2023/01/27 06:01 PMCR- 2023/01/09 CRDT- 2023/01/26 02:42 PHST- 2022/09/15 00:00 [received] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/26 02:42 [entrez] PHST- 2023/01/27 06:00 [pubmed] PHST- 2023/01/27 06:01 [medline] PHST- 2023/01/09 00:00 [pmc-release] AID - 1045561 [pii] AID - 10.3389/fphar.2022.1045561 [doi] PST - epublish SO - Front Pharmacol. 2023 Jan 9;13:1045561. doi: 10.3389/fphar.2022.1045561. eCollection 2022.